Navigation Links
New cancer drug screening technique more closely mirrors reality
Date:3/14/2010

BOSTON Improving on traditional screening tests for potential anti-cancer drugs, scientists at Dana-Farber Cancer Institute have developed a laboratory technique that more closely simulates the real-world conditions in which tumor cells mingle with the body's normal cells.

Because these neighboring cells key components of what is known as the "tumor microenvironment" can alter the effectiveness of anti-cancer drugs, the new technique may help researchers narrow the field of possible therapies more quickly and identify the most promising candidates more readily. The technique, described in a study published online today by the journal Nature Medicine, can be used to study a wide variety of cancer cells that infiltrate an equally wide range of normal tissues, the authors say.

"Despite their often impressive results in the laboratory, for every 100 potential anti-cancer therapies administered in patients in clinical trials, only about eight prove safe and effective enough to receive Food and Drug Administration approval," says the study's senior author, Constantine Mitsiades, MD, PhD, of Dana-Farber. "This success rate is clearly not as high as we would like it to be, and one reason may be that so far we haven't had a good way to account, at the earliest stages of laboratory testing, for the impact of the tumor microenvironment on these drugs."

In conventional drug screenings, different types of cancer cells are exposed to hundreds or thousands of compounds under laboratory conditions in which only tumor cells are present. The compounds that prove best at killing tumor cells are then earmarked for further study.

A shortcoming of this approach, Mitsiades says, is that "in the human body, tumor cells don't grow in isolation, but come in contact with a wide variety of non-malignant cells. Many of these 'accessory' cells support one another through direct contact or by producing substances known as growth factors. Tumor cells can take advantage of these signals to fuel their own growth."

Evidence from a variety of studies suggests that these otherwise normal elements of the tumor microenvironment can impede the effectiveness of anti-cancer drugs and allow cancer to become resistant to different therapies one of the biggest challenges in oncology.

To get a better understanding of this phenomenon and develop treatments to address it, Mitsiades and his colleagues developed a technique in which tumor and normal cells are "co-cultured" that is, grown together and exposed to hundreds or thousands of compounds in large-scale screening tests. In the technique, dubbed "cell-specific in vitro bioluminescence imaging," or CS-BLI, the cancer cells in each sample are equipped with a gene that makes them glow a process unaffected by the normal cells nearby. By measuring the amount of light emitted by each sample after treatment, investigators can determine which compounds are most proficient at killing tumor cells, and whether this effectiveness changes when normal cells are around the tumor. (To make sure the candidate drugs aren't also killing normal cells, researchers can do a "counter-screen," in which they measure the effect of each compound on the normal cells.)

While there are other techniques for screening drug activity in co-cultures of malignant and normal cells, they either involve radioactivity or entail a time-consuming process of data capture and analysis, rendering them too cumbersome for large-scale studies, Mitsiades remarks.

With CS-BLI, Mitsiades and his colleagues have identified numerous compounds that acted powerfully against isolated samples of tumor cells but were significantly less effective against the same types of tumor cells co-cultured with non-malignant cells. Perhaps surprisingly, they also identified some compounds which are more effective against tumor cells mixed with non-malignant cells than against tumor cells alone.

In this latter category, researchers found a particular compound that was more active against myeloma tumor cells, both in laboratory cultures and mice, when the cells were in contact with healthy cells of the bone marrow their usual location in patients. The compound also prevented the myeloma cells from responding to growth signals produced by the bone marrow cells. With conventional techniques, candidate drugs such as this one would have gone completely unnoticed, Mitsiades observes.

He emphasizes that CS-BLI is not a technique for predicting which anti-cancer agents will be effective in individual patients, but can help researchers identify which agents are the best prospects for additional investigation.

"It will be of use in prioritizing candidate drugs for further rigorous study of their properties before embarking on clinical trials," he remarks. "This technique may show that the classical methods of studying candidate cancer drugs in laboratory conditions have overestimated the effectiveness of some agents, and underestimated others.

"The technique also provides a powerful tool for determining which biological mechanisms allow cancers to become resistant to certain treatments and which new therapies can neutralize those mechanisms. Hopefully, combining such new therapies with other, established or investigational, treatments may contribute to improved success rates of clinical trials."


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... ... the Pennsylvania Cable Network (PCN) during the summer of 2016. The program was ... provided by the United States Department of Health and Human Services Administration. ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance ... today for its 33rd Annual Issues & Research Conference, March 2-3, 2017, ... of the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental Laboratories ( ... patients about the safety issues related to dental restorations. According to the American Academy ... to reach $6.4 billion in 2018 with more than 30 million Americans missing all ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY ... ... reducing loss of blood during surgeries, lowering the risks of ... decreasing risks of SSIs. The patient warming systems can be ... warming systems.These benefits in turn reduce the stay at hospitals ...
(Date:12/8/2016)... -- KEY FINDINGS The global medical lifting ... reasons for growth of the medical lifting sling market ... diseases, high recovery cost of injuries and government initiatives ... sling refers to an assistive device that helps caregiver ... to the lift and hold the patient. It is ...
Breaking Medicine Technology: